Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics在第34届EORTC-NCI-AACR研讨会上作全体口头报告，介绍CBX-12的首次人类研究结果
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
积极的FIH安全性和耐受性数据支持将CBX-12推进到多项II期研究结果显示疗效的早期迹象，伴有良好的安全性 康涅狄格州纽黑文, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Cybrexa...
Cybrexa Therapeutics to Present at Upcoming Investor Conferences in June
02 juin 2022 08h30 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics公布数据显示抗原独立肿瘤靶向疗效和强大潜力的早期信号
26 oct. 2021 12h26 HE
|
Cybrexa Therapeutics
Cybrexa用于实体肿瘤的主要治疗候选药物CBX-12在既往接受过多种治疗方案的患者人群中显示抗肿瘤活性和强大疗效信号CBX-12和肿瘤免疫疗法联合试验预计将于2022年末启动关于加速批准用于卵巢癌和非小细胞肺癌的计划将根据2022年末开始的2期扩展队列进行评估 康涅狄格州纽黑文, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Cybrexa...
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting
26 oct. 2021 08h00 HE
|
Cybrexa Therapeutics
CBX-12, Cybrexa’s lead therapeutic candidate for solid tumors, demonstrates anti-tumor activity and robust efficacy signals in a heavily pretreated patient populationCBX-12 and IO therapeutics...
Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
28 sept. 2021 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
Cybrexa Therapeutics将出席AACR-NCI-EORTC分子靶向和癌症疗法虚拟国际会议
28 sept. 2021 07h00 HE
|
Cybrexa Therapeutics
康涅狄格州纽黑文, Sept. 28, 2021 (GLOBE NEWSWIRE) -- 通过自己的alphalex™多肽药物偶联（PDC）平台开发新的治疗方法的专注于肿瘤学的生物技术公司Cybrexa...
Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference
10 sept. 2021 09h57 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021
04 août 2021 11h50 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
Cybrexa Therapeutics宣布NAR Cancer刊发经同行评议的相关论文
09 juin 2021 09h12 HE
|
Cybrexa Therapeutics
康涅狄格州纽黑文, June 09, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics是一家致力于肿瘤学的生物科技公司，通过其alphalex™多肽药物偶联物（PDC）肿瘤靶向平台开发新一代疗法。该公司今天宣布，NAR Cancer发表了有关Cybrexa候选先导化合物CBX-12的经同行评议研究。NAR...